Betamethasone dipropionate and calcipotriol foam as an adjuvant therapy in patients with severe psoriasis treated with biologic drugs

Introduction:
Introduction of novel biologic treatments for plaque psoriasis has revolutionized treatment approach and improved outcomes in patients with moderate-to-severe disease. New groups of biologics are even more effective and better tolerated compared to their predecessors. However, none of the currently available biologic drugs is associated with complete skin clearance in all treated patients. Moreover, the requirement to stop therapy in accordance with previous therapeutic program guidelines in Poland may have contributed to a gradual loss of efficacy of biologic drugs. Betamethasone dipropionate (BD) and calcipotriol (CAL) foam is the most widely studied topical drug in the therapy of mild forms of psoriasis. Numerous clinical trials have demonstrated its excellent efficacy not only in reactive therapy but also in preventing recurrences through the implementation of proactive therapeutic regimens.

Case report:
We present 2 cases of patients with severe psoriasis and psoriatic arthritis who were treated with biologic drugs with incomplete remission of skin lesions. Topical therapy with BD/CAL foam was introduced to treat refractory psoriatic lesions, leading to excellent outcomes.

Conclusions:
The reported cases show that therapy with BD/CAL foam may be an effective adjuvant treatment of psoriasis in cases of incomplete and unsatisfactory response to systemic therapies, including biologics.